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arhieved r*O% redwtbm b~v&ul*r ectopic d&olari- 
mtkm during inpaden, ,hempy. Mean ventricular ec,opic 
depokxizadorn dwreared from 15.792124 h to 2.357124 h on 
optimal dosage (p < 0.0,). Paine patients had paired 
ventriodar cc,@ depafariatiins; four of dx nine had 
299% red”c,io” ofthese b&s.. Anlong seven pa,ienLr wilh 
nonsurtined ventricular tacbycardia. Pve had 100% elim- 
ination of,hDsp even(s wi,h indeainide and all had a991 
r&&n in lbese even&. lndecainide prolonged ,ba PR 
inlprval44 * 27 ms (,, < O.wO1, and ule QRS interval 11 
detected. Side cPkee(s during rhort-term thtrnpy were mild 
and did “a, require dien,iiu~,ion of the drug. EEicary 
Indeceinide was developed as a replacement for aprindine. 
an antiarrhythmic drug previously reported to be effective 
for lrealmen, of venlricular arrhythmia, but aswciated ulth 
frequem cential nervous system side effect5 (1, and rare 
episodes ofhepadfis (2) and agranulocymsis (3.4). Indecam 
ide has some sfruefural similanty lo aprmdine, bu, IS ncf a 
metabolitr. Although further development of aprindine hsr 
been susoended because of ride elfeclr. indecainide aooears 
to have a lower frequency of these aide effects in labdr&ry 
animals. indecainidc has an climinauon half-life of 3 10 5 h in 
a variety of species (5). The drug is metabolized 10 deiiso- 
propyl indecainide in the liver and both indecainide and IS 
melabolite are excreted in the urine (6) 
lndecainide decreaw rhe maximai upstroke velocity of 
phase 0 of the action potenlial PI,.,) in both Purkinje fibers 
and papdiary muscles without prolong~nf the action poten- 
hal durauon G.8). In twlaled rabbit heart preparations it has 
rmmma, eRecr on the sinu and ~lnoventncular ,A”, nodes 
(91 In bom:~r~. inlravenous mdecam!de Gmdarly hat mmt- 
ma, effect on the refrxlory psrim(~ of Ihe sintu and AY 
node, but prolong AH and HV conduction limes and 
mcrcax~ QRS duratlon (IO). lndecainide is therefore a 
Vaufihan Wdliams class IC agen, (11-13). 
A, this lime. only limited data are available concernmg 
the cbmcdl rriicacv ufindecainide. Usw programmed elec- 
lncal ~llmulalmn. inducible ventncular t&y&dia WLF sup 
premed by mtravenous indecamide in 3 of I5 patients (141. 
There are no published repor’, of the use of mdecamide for 
suppre?Gx of ventricular ectoptc dcpolarizafioor. although 
several ah\uac,s (15-17) have descntbed prelimitmry experi- 
ence with ill use for trealment of ~cmricular ectopxc depo- 
lilrizalmn~. 
We studied oral indrcaimdc for suppressmn of ventncular 
eclopic drpularizations m electively hospdalized patienls 
durmg short-lerm placebo-controlled dose-ranging rin&lc 
hhnd therapy followed hy open label outpatient therapy for 2 efficscy and tolerance during outpatient therapy with a 
years. maximal dose of 4Oil mg!day of indcuainide. 
Twenty-four hour ECG recordings. Continuous 24 h ECG 
recordings were obtained on days I and 2 (pretreatment 
Methods 
placebo period), 3. 5. 6. 8. 9 and It (first and third day of 
each treatment period), and on days 12 to 15: recordings 
Selection of patients. Patients who were 21 to IS years old were also obtained at each outpatient follow-up visit during 
were eligible ior this protocol. All had ~30 ventricular the 2 years of follow-up therapy. Analysis of the 24 h 
ectopic depolatizationsih on a 24 h electrocardiographic recordings WBE obtained by qualilative review of a complete 
(KG) recording white receiving no antiarrhythmic therapy. compressed printout of the recording and also by quantita- 
Paired vemricutar ectopic depolarizations and nonsustained live analysis (Cardiodala Corp.). This method reported an 
ventricular lachycardia events were allowed in this study. average of 102.5% (range 79 to 158%) of the ventricular 
Patients were required to sign B written consent form. This ectopic depolarizations found by manual counting (18). 
swdy WBS approved by the lnstttutional Review Board of Indicarion for dose adjustment during inppalienl thrropy 
Hennepm County Medical Ccntcr on August 17, 1982. was determined by qualitative review of the complete com- 
Patiems were excluded if they had symptomatic vent& Pressed ECG printout. Unless complete elimination of ven- 
cutor arrhythmia causing hemodvnamic compromise or if tricular ectopic depolarizations was obtained or adverse 
they had a-heart rate <5l?heatsi&. Patients &lb second or experiences &cur&d, dosage was increased. 
thrrd degree AV block or R QRS duration XI.12 s were Twelve lead ECG. Electrocardiograms were obtained by 
excluded. A systolic blood pressure 290 mm Hg was re- a computerized system (Hewlett-Packard model 564X). 
quircd. Women of childbearing potential were excluded. This system provides a computerized measurement of the 
Patients who had had a myocardial infarction within 3 weeks PR. QRS and QTc intervals. We calculated JTc dxration. 
before the study. or who had New York Heart Association where JTc = QTc - QRS interval. These ECGs were 
functional class IV congestive heart failure. cardiogenic obtained just before the morning dose of medication aon days 
shock, wgpccted digit& toxicity. significant hepatic or I. 3, 5, 8, II, I2 and 15. Additionally. a I2 lead Et:G was 
renal dysfunction or other terminal conditton were excluded. obtained 81 each outpatient visit. 
Patients were cxcludcd who were being treated with other Blood level assays. Blood WBE ob!ained for lod:crdnide 
antiarrbythmic agents. including beta-adrenergic blocking level measurerncnts on the final day of each dos, during 
dmgs. inpatient dose ranging just before the morning dose days 5. 
Patient characteristics. Eight men and two women were 8 and I I). Additionally, on the final day of dosing (day 12). 
studied. Their mean age aa$ ht years (range 43 to 70). Their blood was obtained just before dosage and 0.5, I, 1.5.2.3.4. 
principal cardiovascular dragnoses were coronary artery 6.8. I2.24.36.48and72 hafierthcfinaldoseofindecainide. 
dlseasc (five cat~cntst. ddared cxdiomvonathv two Troueh olasma levels were also obtained durhw each fol- 
paientrl. rmtrai valve prolapse (one patientiand nd identt- 
ficd rtrucmral heart disease (two patients). Eight patienls 
had episodes of palpitation: one of there also had syncope. 
The patient with mitral valve prolapse and the two palients 
without heart disease all had symptoms related to anhyth- 
mia. Eight of the IO @ents had previously received other 
anrlarrhythmic drugs, an weragc of 1.8 (range I to 31 drug5 
per patient had been discontinued beaux of in&ctiveness 
or side etTecu. 
Study protocol. Aftcr admission to the hospital. patients 
rcccwd an oral placeho every 8 h on days I and 2; SO mg of 
oral indrcainide every 8 h on days 3 to 5: 75 mg every 8 h on 
day\ 6 to 8; IftO mg every X h 0; days 9 10 I I _a sin& dose 
of 100 mg of indecainidc on the morning of day I? and then 
placeho every 8 h for the remainder of that day and on days 
I3 to I5 
,Ifiw rompl~rinu of rhr prorwol. patients were dia- 
charged on the opttmal dare of oral indecainide for long-term 
follow-up. They were evaluated monthly durmg the first year 
of outpatient therapy and rhen every other rnonth during the 
second year. Dosage adjuslnwL wa dtlowsd to oprimiro 
low-, ;isit on outpatient therapy. These p&a sampler 
were analyzed for indecainide and desisopmpyl indecainide 
by Eli Lilly and Company. 
Bled wrr~ also ubtnined fur clinicul hbomkvy frsts 
during initial placebo therapy, on day 3 of each inpatient 
dosage of indecainide. on the last day of inpatient placebo 
washout therapy and on each outpatient visit. Testing in- 
cluded a complete blood chemistry panel, antinuclear anti- 
body titer and hcmagram including white blood cell count. 
Urine was obtained for urinalysis at each of these times. 
Additionally, standing and supine blood pressures were 
obtained hy auscttltation. 
Hatnod&nic data. Systolic time intervals and M-mode 
and two-dimensional echocardiograms were obtained during 
initial placebo therapy and on the final day of the tast dose of 
indecainidc during inpatient therapy. The QS, interval. heart 
rate-adjusted left ventricular ejection time (LVET,). rate- 
v)‘ated preejection period (PEP,). PEP/LVET. ejection 
fractiott by Mmode. velocity of circumferential fiber short- 
erring. left ventricular end-dinstohc dimension, left ventricu- 
lar end-systolic dimension and left ventricular change in 
diameter were calculated by standard method. Using rhe 
apical four chamber view of the twodimensional echocar- 
diagram, the let? ventricular end-diastolic and end-systolic 
area and the left ventricular area change were calculated by 
planimetry using previously reported method (19). 
Heart rate. standing and supine blood p:essure by aus- 
cultation and systolic and diastolic blood prcssurc powral 
change in milhmeterr of mercury were obtamed during 
placebo therapy and on the final day of indecainide inpatient 
therapy. 
Damge adjustment during inpatient therapy. During dose 
titration, the indccainide dosage was increased to the next 
level after each 3 davs of dosine unless comolete elimination 
of ventricular atopic depol&ations was detected by qual- 
itative review of the 24 h ECG on the final day of sach dobe 
or unless one or more clinically Ggoificant adverse experi- 
ences occurred. Dosage was nut increased if the PR interval 
was >280 ms, the QRS interval was >I50 rns or the QTc 
interval wus 2480 ms. These intervals were obtained by 
computerized analysis of the I2 lead ECG. If any of these 
conditions occurred, the protocol war advanced to day I? 
(final dosing day) to obtain pharmacokmetic data and inde- 
cainide washout data. 
Data analysis. The total number of ventricular ectopic 
depolarizations per 24 h was calculated for the average of the 
2 initial placebo days, the final day of dostng at each 
inpsticnt dosage Icvel. the last dosage administered. the 
average of all three placebo washout reccrdings (days 13 to 
IS) and for each of the recordings obtained during the 
outpatient follow-up. The means z SD for these data were 
calculated for each of :he time periods. Similarly. the aver- 
age number of paired wntreularectoprc depolarizuuons per 
24 h and evaus of nonrustaincd ventricular tachycardia per 
2A h were calculvted for the group. The percent wppreanon 
of vcntr~cular ecropic depolanzations was calculated fur 
each panent by comparing r?ch time period with the initial 
placebo period. Statistical comparisons between each pcnod 
of treatment and initinl placebo period were ma& by one- 
way analyw of variance and ulso hy paired r tesi (using 
Dunnetl‘s correction for mulliple r lesrsl. In addition. the 
arrhythnua data were transformed by adding I :o each value 
and then calculating the natural logarithm because these data 
are not lbkeiy to be normally drstnbuted. Furthermore. the 
nonpwamrtrx Wilcoron sigucd-rank test was ssed to cum 
par; the data during inp&nt dosing and at I month of 
thewpy with that during the intial placebo period. 
In a samilar matter, the mean data were calculated for 
each of the ECG intervals, dally dosage. indcca%tc tcvct~, 
indecainidr met&olite level> and white blood cell count>. 
Statistical comparisons were made by analysis of varwwz 
and paired r test. Finally. the paired r test was used to 
compare the mean echocardiographtc and hemodynamtc 
data (blood pressure and heart rate) during initial placebo 
and optimal indecairude therapy. Terminal elimmauon half- 
lhfc was calculated by standard methods. The relations 
among arrhythmia suppression. pharmxokinetica and ECG 
intervals were assessed by correlation coefficients. 
Results 
Supprrrsian of ventricular e&pie depolarizations tinpa- 
tirnt thrrapy) (Table 11. Dunng imtird placebo therapy. 
patients had an axerage of 15.792 2 12.095 ventricular 
ectapic depolarizations/24 h. Their frequency prugress~vely 
decreased as the dose of indecainide increased (p < O.C@Ol 
by analysis of variance). On optimal dosage of indecamide 
durmg mpauent therapy. the mean number of ventriculsr 
rctopx depolarizations was reduced to 2.357 + 3.389 !p < 
0.01 verw< initial placebo by I rest); their frequency returned 
to baseline during washout plrcebo therapy (p < 0.01 versus 
final dose by I test). 
Each mdividual putienl‘s percent suppreprion of ventri- 
culer eclopic depolariwlions from initial placebo was cnlcu- 
laked. On opiimal dosage ofindecainide, 8 oflhe 1Opatienis 
achxeved ~80% suppression. The mean percem suppression 
on Rnal dose was 78 2 34% (p < 0.01 versus initial plzcebo 
by I test). Only one patient obtained complete eliminalion of 
ventricular ectopic depolarizations (Fig. I). Four palien!> 
rcspundcd (~80% suppression1 to the lowest indecainide 
dose IISO mcidav). 3 addilional rxaticnts resrronded to 225 
r&day and i pa&u responded tb 300 m&y: thus 8 of 10 
patients achieved ~80% suppression of ventricular ectopic 
depolarizations. 
Repetitive ventricular eelapia depolarizations (inpatient 
therapy) (Table 2). Paired ventricular ectopic depnlariza- 
Cons were detected during inilial placebo therapy in 9 of the 
IO patrents. The mean number of paired ventricular ectopic 
deoolarizalions decreased from 814 + 2.010 on placebo Lo 42 
2 ?2/24 h on final indecainide dosage (p < O.C&l by analysis 
of variance and p c 0.01 versus initial placebo by Wilcoxon 
test). Paired ventricular ecfopic depolarizations returned 
during placebo washout therapy in all patients (p < 0.01 
versus final dose by I test). Of the nine patients with paired 
ventricular ectopic depolarizations, four had essentially 
complete elimination (8% suppression) and one other 
patient had 98% reduction; overall. six of nine patients had 
280% suppression of pairs. 
R,,ns of nons,,sfained venr,;calar lochycordin were de- 
tected in 7 of the IO patients during initial placebo therapy. 
These patients bad a mean of 242 Y? 614 runs124 h of 
nonsustained ventricular tachycardia on placebo and a mean 
of I + 3 runsi h during optimal indecrdnide dosage (p 4 
O.wOl by analysis of variance and p < 0.01 versus initial 
placebo by Wilcoxon tcsl). Episodes of nonsustained ven- 
tricular txhycardia returned in all patients during placebo 
washout therapy (p < 0.01 versus final dose by I lest). Of the 
seven patients with nonsustained ventricular lachycardia on 
placebo therapy. five had IWW elimination and two had 
nearly complete elimination of tachycardia. No patient de- 
veloped aggravation of ventricular arrhythmia during short- 
term indecainide therapy. 
Pharmacoktnetics. (Table 3). The mean elimination half- 
life ofindecainidc was 10.3 * 2.3 hand that ofits metsbolite 
averaged 15.7 * 4.7 h. The trough plasma levels of indecai- 
nide and its desisopropyl indecainide metabolhe are shown 
in Table 3. No correlation was found between percent 
suppression cd ventricular ectopic depolarizations on final 
dose and iodecainide plasma level (r = 0.08). indecainide 
plasma half-life (r = 0.17). metabolite level (I = 0.231 or 
metabolite half-life (r = OStlW8). 
ECG intervals (Table 3). The PR and QRS intervals 
increased significantly during shon-term indecamide therapy 
(p < O.wOI versus initial placebo by analysis of variance) 
whereas the QTc interval did not change (Fig. 21. Becauce 
the QRS duration increased and the QTc interval remained 
unchanged, the ITc interval was actually shorter on mdecar- 
nide therapy $ c 0.05). No corrclatwn was found between 
suppressi& of ventricular ectopic depolarizations and the 
change in either the PR ir = 0.04) or the QRS (r = OS@61 
interval. However, an average increase of44 ? 27 ms for the 
PR interval and I I + 9 ms for the QRS interval ~3s detected 
on optimal dosage. 
Ecbocardiogrsphic and hrmedynamic data (Table 4). No 
changes in systolic time intervals and M-mode or two- 
dimensional echocardiographic measurements were de- 
tected during short-term indecainide therapy in comparison 
with placebo therapy. No significant change /n heart rke was 
detected on iodecainide therapy: the mean rate WBE 78 + I9 
katslmin on placebo therapy. 79 + 17 katslmin on final 
indecainide dose and 78 ? I9 beatsimin durine placebo 
washout therapy. No change during indecaioide therapy in 
standing or supine systolic or diastolic blood pressure or 
systnlic or diastolic postural blood pressure change was 
detected. 
Long-term therapy (Table 5). During long-term therapy 
for 2 years. suppression of ventricular arrhythmia was 
consistently maintained for five patients, whereas the other 
five patients were withdrawn from indecainide. Seven of the 
eight patients who initially responded to indecainide dunne 
inpatient therapy continued to respond at I month of therapy 
during outpatient treatment. The patient who lost respon- 
siveness to indecainide at the I month evaluation was 
withdraw from therapy at that time. This patient’s ECC 
mtervals continued to show evidence for drug etT:ct despite 
lack of ctiicacy for reducing ventricular ectopic ~iepolariza. 
lions. The two patients who did not respond dunng $nmat 
npatient dowg remained nanresponders durin: outpatient 
therapy and were withdrawn from indecainide a,isr I and 7 
months of treatment, respectively. Two other p:dients were 
wahdrawn from indecainide during long-term therapy lree 
Me etfccts). 
Tlw mum number of total vrnrriculoi rcrooic depolari- 
x!ions prr 24 h was signi%antly redwed after I month of 
therapy and remained suppressed dwing the :. years (range 
of rhc monthly means 81 to 4.574 per 24 ‘I). The msan 
percent suppression of anhytbmk dunng th:se 24 months 
for all 24 h recordings was 87 f 15% (range of the momhly 
means 70 to IOO). The mean number of pared ventncular 
ectopx depolarizations per 24 h during lo ~g-term therapy 
was I I z 36124 h (range of the monthly means 0 to 69124 hl 
and the mean number of events of nonsus!ained vemricular 
tachycardia was I 5 8124 h (range of the monthly means 0 to 
12124 hl. 
Darq 2 yews of rherapy. the mean PR interval was 200 
z 6 ms (range of the monthly means I84 to 211 ms) as 
compared with 172 r I2 ms on initial placebo therapy. The 
mean QRS interval was 104 ? 4 ms (range of the monthly 
means 91 to Ill) compared with 92 + I3 rn? on initial 
placebo therapy. The increase I” the PR and QRS inlervals 
remained stable during the 2 years. Mean indecainide dosage 
gradually decreased from a mean of 253 i: 80 mglday at I 
month of therapy to I75 c 94 mdday at 24 months. Indecain- 
jde trough plaamalevelsaveraged 445 _t 132 w/ml duringthe 
24 month. of therapy (range of the monthly means I98 to 
805). Indccamide metabolite lexls averaged 51 2 37 ndml 
duringth: 24months(rangeofrhemonthlymeans26to Il3). 
by indecainide. The count was 7.9 3 2.7 x 10’ on initial 
placebo therapy and 7.9 I 2.9 x IO’ on tinal inpatient dose; 
it averaged 7. I z 0.6 x IO’ for the entire 2 yws of therapy 
and was 7.0 f 2.2 for the five patients still or, therapy at 2 
year\. Other blood tests. including xrum el~:c~rolytes. he- 
ram antinuclear andbody and hemoglobin. were not signifi- 
cantly changed during long-lenn therapy. 
Side &cls. The mpaiienl dosing protocol was intcr- 
Patient .I had dose ranging discontinued be&se 
ofthe development of right bundle branch block and Patient 
7 because of nonspecific widening of the QRS interval. Both 
patients were asymptom& and achieved >80% reduction 
in ventricular cctopic depolarizations on doses of indecai- 
nidc thal did not produce marked widening of the QRS 
complex. 
Thrpp pnriwnir developed dizziness and blurred vision 
although dose ranging was limited because of this effect only 
in Patient 10, thir pa&t also achieved acceptable supprer 
sion of arrhythmia on doses ofindecainide that did not cause 
side elfecls. 
During long-repin rherapy, three patients (Patients 2. 5 
and 8) were withdrawn from indecsinide because of poor 
efficacy as described. One was withdrawn after 7 months of 
therapy because of impotence (Patient 4) and one patient 
was withdrawn because of incomplete wwession of non- 
sustained ventricular lachycardia’after 1 month of therapy 
and second deerce AV block (Patient 7). Other side effects 
that did not r&ire discontinuation of treatment occurred 
during long-term therapy. These included intermittent occur- 
rence of asympromaric right bundle branch block in Parient 
I: one patient each reported intermitlent dizziness. headache 
and blurry vision. 
Discussion 
In this study. indccainidc was etTective for suppression of 
total and repetitive ventricular ectopic depolarizations dur- 
ruplcd m five patwlb. Twu patients had dose ranging 
dircuntinued because of complete (Paient 6) or essentially “clcaly OrCl,C”mrClenli”l fiber 3ho”aing 
ing short-term therapy. as previously suggested m prebmt- 
nary repons (15-17). In patients who indially responded tu 
indecainidc. efficacy was usually maintamed during 2 years 
of therapy. 
Classificalion of indecainide. lndccaimde is a &SC IC 
antiarrhythmic drug based on previour electrophysiologic 
studies in both laboratory animals and humans 17-10). In thn 
study, indeeainide prolonged Ihe PR and QRS intervals 
without prolongrng the QTc or JTc mtcwals. a finding that i) 
consistent with clas$Rcation ns a class 1C agent. We found 
the prolongation of these ECG effects to be stable during 
long-term therapy for up lo 24 months. 
Pbarmacokinetics. The plasma elit%xian half-life of I”- 
decainide in animals is reported 10 hc 3 10 5 h 151. However. 
we found the half-life in patients fo ho conriderahly longer at 
10.3 t ?.? h. ‘This 1onp.w Mf-life su,psts ihat twice daily 
dosing with indecainide may bc fusible for many patients. 
The major metabalite of inde<.dnide. derinopropyl indew. 
nide. had a longer eliminalion half-life than did mdecainide in 
our study, but the plasma levels of this metabolile are only 
approximalely lC% of those of the parent compound. The 
antiarrhythmic effects of this melabolite are unknown. 
We l~ere unable to detect a correlation between rupprcs. 
sion of wntricular eclopic depolarizauons and either m:Js- 
cainide pharmacokinelics or ECG intervals. The PR and 
QRS intervals did increase in a rtepwis‘ manner a, the dose 
of indecainide was increased. whereaa suppression of 
arrhythmia occurred at the lowest dose for several paUents. 
It is possible that testing thex correlations ill luwcr dose5 of 
mdecainide than were used m our study might reveal wgnlf- 
icant relations among these variable\. 
Cardiovascular ride effects al indecainide. We iound “0 
adverrc c&w of ihxdccainidc on lef! ventncuiar fwactitin a 
ucmr~ular arrhylhmm. Specifically. no pdtwnt had ag~rava- 
tion uf wntncular arrhythma although asymptomatic bun- 
dle branch block and second degree AV block occurred I” ? 
uf IO patwnts We did not de;ecr any change in echocdrdio. 
graphic or hemodynamic variatles of left ventricular hnc- 
tmn or syitolic time inlervB1s and no congert~ve bean failure 
occurred The apparent absence of a negative ,norrap~c 
effed oi mdecainide i I) may d&r an xhanvq% lor thn 
cnmpoimd. although further study of ;he drug in p&nR 
with impaired left venlricular fuunctwn 1s required. Aggrava- 
lton of arrhylhmis has been rcponed in vxne patienls with 
most anlwrhvthmx acen;s 120). It can be expected lhel this 
wdI be obwved ailh-irdecaimde when S&r numbers of 
patienta are $iudied. pan’wlsrly those w!ih more left yen- 
tricular dy5funtiian than rw pattents had. However. II IE 
encouraging tbar aggravatior. of arrhythmia was not seen in 
this small clmical series. Non. rrdiovascular aide elT~ct5 Of 
indccalmde. primarily related to Ihc cenlral rxrvous system. 
were mdd and responsive lo dovge adjustment. 
Conelusions. lndecaimdc IP a promrsmg new antlarrhylh- 
mic drug rbal is effecrive and well loicralcd in marl patients. 
It mentr fullher study in larger nui>bers of patlent?. 
published (21) that described an 85% shon:tcrm r&se lo 
oral indccainide. orolonmlion of the PR and ORS inlervals 
